I-125-CLR1404 as a (NEO) adjuvant treatment option for triple-negative breast cancer

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201500071C
Awardee
Awarding agency
Obligated
$2,292,085

Award facts

Opportunity
  • N43CO5704291 Solicitation number
Contract value 100% obligated
$2,292,085.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Madison, WI 53716, USA
Research
SBIR Program Phase I Action

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 5 $0
Other Administrative Action 4 $0
Exercise an Option 3 $1,999,370
Exercise an Option 2 $0
Other Administrative Action 1 $0
Original award $292,715

About this award

This is a $2,292,085.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Cellectar Biosciences, Inc., a small business, under the Small Business Innovation Research (SBIR) Program. The contract is for the research and development of I-125-CLR1404 as a treatment option for triple-negative breast cancer. The contract has a period of performance through December 31, 2019.

Quick answers

Who was awarded contract HHSN261201500071C?

HHSN261201500071C was awarded to Cellectar Biosciences, Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2015.

How much is contract HHSN261201500071C worth?

The government has obligated $2,292,085 on HHSN261201500071C.

Was contract HHSN261201500071C competed?

The extent of competition for HHSN261201500071C was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award